Prednisone: Uses, Doses, Side Effects, and How It Compares to Other Corticosteroids

What Is Prednisone and How Does It Work?

Prednisone is an inactive prodrug. The liver converts it to prednisolone via 11-beta-hydroxysteroid dehydrogenase, and prednisolone then binds glucocorticoid receptors in virtually every tissue. That receptor binding suppresses NF-kB, reduces prostaglandin synthesis, and shifts immune cells toward anti-inflammatory phenotypes. Glucocorticoids also stimulate gluconeogenesis in the liver, which explains why blood glucose rises predictably with higher doses.

The drug's biological half-life sits between 18 and 36 hours, which is why once-daily morning dosing is standard for most chronic conditions. Morning dosing mimics the natural cortisol surge that peaks between 6 a.m. and 8 a.m. and minimizes HPA-axis suppression compared with evening administration. The FDA label for prednisone tablets specifies administration with food to reduce gastrointestinal irritation.

Prednisone belongs to the same glucocorticoid family as cortisol but carries roughly four times cortisol's anti-inflammatory potency at an equivalent weight. It has almost no mineralocorticoid activity at doses below 20 mg/day, so it does not reliably replace aldosterone in patients with primary adrenal insufficiency. Fludrocortisone is required for that purpose.

FDA-Approved Uses and Off-Label Applications

The FDA has approved prednisone across endocrine, rheumatologic, pulmonary, allergic, dermatologic, gastrointestinal, hematologic, neoplastic, ophthalmic, and neurologic conditions. The full approved indication list in the package insert covers more than 30 named diseases. The prescribing information lists rheumatoid arthritis, systemic lupus erythematosus, severe psoriasis, pemphigus, bronchial asthma, and multiple sclerosis as primary indications.

Off-label use extends the reach considerably. Clinicians prescribe prednisone for:

• Bell's palsy (60 mg/day for 5 days, then tapered), where a 2008 Cochrane review found corticosteroids significantly improved complete recovery rates compared with placebo
• Subacute thyroiditis pain control
• Hypercalcemia from sarcoidosis or granulomatous disease
• Immune thrombocytopenic purpura (ITP), typically 1 mg/kg/day for 2 to 4 weeks

In a 2012 Cochrane review of corticosteroids for Bell's palsy, steroid treatment significantly improved the rate of incomplete recovery at 6 months (RR 0.63 to 95% CI 0.50, 0.80).

For asthma exacerbations, the 2023 GINA guidelines recommend a short course of oral corticosteroids at 40 to 50 mg prednisone-equivalent per day for 5 to 7 days in adults who do not respond to bronchodilators alone. Five-day and 7-day courses produce equivalent outcomes for most exacerbations according to trial data. The GINA 2023 report states: "Short courses of oral corticosteroids are effective in preventing early relapse after an acute exacerbation."

Dosing: From Physiologic Replacement to High-Dose Pulse Therapy

Prednisone doses span a 200-fold range depending on indication. Understanding where a patient sits on that range helps predict which side effects are most likely.

Physiologic range (5 to 7.5 mg/day). This approximates the endogenous cortisol production of 5 to 10 mg prednisone-equivalent per day in adults. Used for secondary adrenal insufficiency when mineralocorticoid replacement is not needed. Daily cortisol secretion in healthy adults averages approximately 5 to 10 mg/m² body surface area, equivalent to 5 to 7.5 mg/day of prednisone.

Low-to-moderate dose (7.5 to 30 mg/day). Standard range for rheumatoid arthritis bridging, polymyalgia rheumatica induction (typically 15 to 25 mg/day), and mild lupus flares. The EULAR 2022 guidelines for polymyalgia rheumatica recommend starting at 12.5 to 25 mg prednisolone-equivalent daily, then tapering slowly over 12 to 24 months. EULAR 2022 recommendations specify that initial doses above 30 mg/day are rarely needed for polymyalgia rheumatica and increase cumulative toxicity without added benefit.

High dose (0.5 to 1 mg/kg/day, up to 60 to 80 mg/day). Reserved for severe autoimmune hemolytic anemia, severe dermatomyositis, or moderate-to-severe ulcerative colitis flares. Randomized trial data from the GETAID group showed that 0.8 mg/kg/day of prednisolone induced remission in 60% of steroid-naive severe UC patients at 4 weeks.

Pulse therapy (250, 1 to 000 mg IV methylprednisolone-equivalent for 3 days). Used for optic neuritis, severe lupus nephritis, or MS relapse. Prednisone oral equivalents are rarely used for true pulse therapy; IV methylprednisolone is preferred because of faster onset and predictable bioavailability.

Side Effects: What the Evidence Actually Shows

Short courses under 14 days carry low risk for most systemic effects. Courses beyond 3 weeks at doses above 7.5 mg/day introduce cumulative organ-level risks that are well-quantified in the literature.

Bone loss. A meta-analysis published in the Annals of Internal Medicine found that glucocorticoid-induced bone loss at the lumbar spine averages 8 to 10% in the first year of therapy and 2 to 3% per year thereafter in patients on doses above 5 mg/day. The American College of Rheumatology 2022 guideline recommends supplemental calcium (1,000, 1 to 200 mg/day), vitamin D (600 to 800 IU/day), and bisphosphonate therapy for patients expected to take 7.5 mg/day or more for 3 months or longer.

Hyperglycemia. Prednisone raises blood glucose primarily by stimulating hepatic gluconeogenesis and impairing insulin secretion from pancreatic beta cells. The effect is dose-proportional. A 40 mg/day dose may raise postprandial glucose by 100 to 200 mg/dL in people with normal baseline glucose and produces frank steroid-induced diabetes in a meaningful proportion of patients already at risk. A retrospective cohort study (N=11,855) found that glucocorticoid users had a 2.23-fold increased odds of new-onset diabetes compared with non-users (OR 2.23 to 95% CI 1.93, 2.59).

HPA-axis suppression. Any dose above 5 mg/day taken for more than 3 weeks can suppress the hypothalamic-pituitary-adrenal axis. The degree of suppression depends on dose, duration, and timing of administration. Graber et al. demonstrated that 14 days of 25 mg prednisone daily produced measurable cortisol suppression on stimulation testing in a significant proportion of subjects.

Cardiovascular effects. Sodium retention, weight gain, and dyslipidemia all increase with dose and duration. A population-based study found a dose-dependent increase in cardiovascular events among glucocorticoid users, with the highest-dose group (prednisolone >25 mg/day) carrying a rate ratio of 2.56 (95% CI 2.08, 3.15) for serious cardiovascular events.

Adrenal suppression and the stress-dose question. Patients on chronic prednisone who face surgery, severe illness, or major trauma may need stress-dose corticosteroids. The standard approach is to double or triple the maintenance dose for minor procedures and to give hydrocortisone 50 to 100 mg IV every 8 hours for major surgery, tapering over 48 to 72 hours postoperatively.

Psychiatric effects. Doses above 40 mg/day carry a meaningful risk of mood disturbance, insomnia, and, less commonly, steroid-induced psychosis. The Boston Collaborative Drug Surveillance Program found that psychiatric reactions occurred in 1.3% of patients on doses below 40 mg/day and in 18.4% of patients on doses above 80 mg/day. That seminal pharmacovigilance report remains the reference benchmark for dose-stratified psychiatric risk estimation.

Tapering Prednisone: The Science Behind Slow Withdrawal

Stopping prednisone abruptly after more than 3 weeks at supraphysiologic doses risks secondary adrenal insufficiency. The adrenal cortex, suppressed by exogenous steroid, cannot produce enough cortisol to meet the body's basal needs once the drug is removed.

The taper rate should be calibrated to the treatment duration and the indication. For courses of 4 to 8 weeks, a common approach is to reduce the dose by 10% every 1 to 2 weeks once below 20 mg/day, then by 1 to 2.5 mg every 2 to 4 weeks once below 10 mg/day. The Endocrine Society clinical practice guideline on adrenal insufficiency recommends morning cortisol testing 24 hours after the last prednisone dose to verify HPA recovery before stopping completely.

Patients with underlying disease may flare during the taper. That flare must be distinguished from true adrenal insufficiency. Adrenal insufficiency presents with fatigue, orthostatic hypotension, nausea, and low serum sodium. A disease flare typically recapitulates the patient's original inflammatory symptoms without the hemodynamic features of cortisol deficiency.

A stepwise decision framework used by the HealthRX medical team for outpatient prednisone tapering:

1. Reduce to 20 mg/day at a pace appropriate to the underlying disease activity.
2. Below 20 mg/day, reduce by 2.5 mg every 2 weeks.
3. Below 10 mg/day, reduce by 1 mg every 3 to 4 weeks.
4. At 5 mg/day, check an 8 a.m. serum cortisol before the next scheduled dose.
5. If the cortisol is above 18 mcg/dL, stop prednisone and recheck in 4 weeks.
6. If cortisol is 10 to 18 mcg/dL, hold at 5 mg/day and recheck in 6 to 8 weeks.
7. If cortisol is below 10 mcg/dL, consider formal ACTH stimulation testing.

Prednisone vs. Hydrocortisone (Cortef): When Each Is Preferred

Hydrocortisone and prednisone both suppress inflammation, but they differ in potency, mineralocorticoid activity, and clinical niche.

Hydrocortisone carries a glucocorticoid potency of 1.0 (the reference standard), whereas prednisone is 4.0. On the mineralocorticoid side, hydrocortisone scores 1.0 and prednisone scores roughly 0.8, meaning hydrocortisone provides meaningful salt retention while prednisone provides almost none at typical anti-inflammatory doses. The standard glucocorticoid equivalency table from the pharmacology literature places hydrocortisone 20 mg as equivalent to prednisone 5 mg for anti-inflammatory effect.

Hydrocortisone is the preferred replacement therapy in primary adrenal insufficiency (Addison's disease) and congenital adrenal hyperplasia because its shorter half-life (8 to 12 hours biological) allows three-times-daily dosing that more closely mimics the diurnal cortisol rhythm. The Endocrine Society guideline recommends 15 to 25 mg of hydrocortisone daily in two or three divided doses for adults with primary adrenal insufficiency. That recommendation was updated in the 2016 Endocrine Society clinical practice guideline on diagnosis and treatment of primary adrenal insufficiency.

Prednisone is preferred for anti-inflammatory or immunosuppressive indications where mineralocorticoid effects are unwanted, because the lower mineralocorticoid activity reduces sodium retention, edema, and blood pressure elevation.

Prednisone vs. Prednisolone: Does the Difference Matter?

Prednisolone is the active form of prednisone. In patients with normal liver function, first-pass conversion is efficient and the two drugs are clinically interchangeable at a 1:1 milligram ratio. The difference becomes clinically significant in three populations.

Liver disease. Severe hepatic impairment (Child-Pugh class C) reduces 11-beta-hydroxysteroid dehydrogenase activity and impairs prednisone-to-prednisolone conversion. A pharmacokinetic study found that prednisolone bioavailability from prednisone was significantly reduced in patients with active liver disease, with peak plasma levels 40% lower than in healthy controls. Prednisolone is preferred in this setting.

Pediatrics. Prednisolone oral liquid formulations are more practical in young children who cannot swallow tablets reliably, and many pediatric guidelines (including the British National Formulary for Children) specify prednisolone rather than prednisone.

Inflammatory bowel disease. Budesonide-MMX has displaced prednisolone for mild-to-moderate ulcerative colitis in many centers because of its first-pass metabolism, which reduces systemic exposure. For moderate-to-severe disease, prednisolone remains standard in Europe, while U.S. centers more often use prednisone interchangeably.

At equivalent doses, prednisone and prednisolone produce the same adverse-effect profile in patients with intact hepatic function.

Prednisone vs. Dexamethasone: Potency, Duration, and When to Choose

Dexamethasone is roughly 6, 7 times more potent than prednisone on a milligram basis and has a biological half-life of 36 to 54 hours, making it the longest-acting oral glucocorticoid in routine clinical use. It carries essentially zero mineralocorticoid activity.

Key clinical applications where dexamethasone is preferred over prednisone:

COVID-19 requiring supplemental oxygen or mechanical ventilation. The RECOVERY trial (N=6,425) found that dexamethasone 6 mg/day for up to 10 days reduced 28-day mortality by 17% in patients receiving non-invasive ventilation or supplemental oxygen (rate ratio 0.82 to 95% CI 0.72, 0.94) and by 35% in mechanically ventilated patients (rate ratio 0.65 to 95% CI 0.51, 0.82). That finding, published in the New England Journal of Medicine in 2020, established dexamethasone as standard of care in hospitalized COVID-19 requiring respiratory support.

Cerebral edema. Dexamethasone 4 mg every 6 hours remains first-line for vasogenic edema associated with brain tumors. Its negligible mineralocorticoid effect is an advantage in this setting.

Croup. A single dose of dexamethasone 0.6 mg/kg orally reduces the need for re-presentation to the emergency department. A randomized trial demonstrated that a single oral dose of dexamethasone 0.15 mg/kg was equivalent to 0.6 mg/kg for mild-to-moderate croup, with no difference in return visits or symptom scores.

HPA-axis testing. The overnight 1 mg dexamethasone suppression test uses dexamethasone because it does not cross-react with cortisol immunoassays, allowing accurate cortisol measurement the next morning. Prednisone cannot be used for this purpose.

The longer half-life of dexamethasone increases the risk of HPA suppression relative to an equivalent anti-inflammatory dose of prednisone, which is why chronic maintenance therapy almost never uses dexamethasone.

Fludrocortisone (Florinef): The Mineralocorticoid Prednisone Cannot Replace

Fludrocortisone is the only oral mineralocorticoid available in the United States and the agent of choice for primary adrenal insufficiency, salt-wasting congenital adrenal hyperplasia, and orthostatic hypotension from autonomic failure.

Its mineralocorticoid potency is approximately 125 times that of hydrocortisone. Standard replacement dosing is 0.05 to 0.2 mg once daily. FDA prescribing information for fludrocortisone acetate tablets specifies 0.1 mg/day as the typical starting dose for Addison's disease, adjusted based on blood pressure, serum electrolytes, and plasma renin activity.

Prednisone does not substitute for fludrocortisone in patients with primary adrenal insufficiency because prednisone's mineralocorticoid activity is far too low to prevent the sodium wasting and hyperkalemia that occur when aldosterone is absent. A patient with untreated Addison's disease prescribed prednisone alone will remain at risk for adrenal crisis despite adequate glucocorticoid coverage.

Monitoring fludrocortisone adequacy involves checking supine and standing blood pressure, serum sodium, serum potassium, and plasma renin activity. Plasma renin at the upper limit of normal or mildly elevated suggests under-replacement; suppressed renin suggests over-replacement and sodium retention. The 2016 Endocrine Society guideline recommends titrating fludrocortisone to maintain plasma renin activity in the mid-normal range and serum potassium between 3.5 and 5.0 mmol/L.

Drug Interactions Worth Knowing

Prednisone participates in several pharmacokinetic and pharmacodynamic interactions that change either its own exposure or the drugs co-administered with it.

CYP3A4 inducers (rifampin, phenytoin, carbamazepine, St. John's wort) accelerate prednisone metabolism and can reduce systemic exposure by 40 to 60%, potentially causing therapeutic failure. Dose increases may be needed. The FDA warns in prescribing information that drugs inducing hepatic microsomal enzymes may reduce corticosteroid efficacy and require dose adjustment.

CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin) slow prednisone metabolism and increase prednisolone exposure, raising the risk of Cushing's features even at standard doses.

NSAIDs. Combining prednisone with NSAIDs doubles the risk of peptic ulcer disease compared with either drug alone. A case-control study found that the combination of corticosteroids and NSAIDs carried an odds ratio of 14.6 (95% CI 6.1, 35.0) for gastrointestinal bleeding compared with NSAID use alone.

Live vaccines. Doses of 20 mg/day or more for 14 days or longer are generally considered immunosuppressive enough to contraindicate live vaccines (MMR, varicella, yellow fever). The Advisory Committee on Immunization Practices recommends waiting at least 1 month after stopping high-dose systemic corticosteroids before administering live vaccines.

Warfarin. Prednisone may increase or decrease INR variably. Closer INR monitoring is needed when starting or stopping prednisone in patients on anticoagulation.

Monitoring Patients on Long-Term Prednisone

Patients taking more than 7.5 mg/day for more than 3 months require proactive monitoring for the complications outlined above. The HealthRX medical team uses the following minimum surveillance interval:

• Fasting glucose or HbA1c every 3 to 6 months
• Blood pressure at every visit
• Dual-energy X-ray absorptiometry (DEXA) scan at baseline, then every 1 to 2 years
• Serum potassium and sodium every 3 to 6 months if on higher doses
• Ophthalmology referral at 1 year to screen for posterior subcapsular cataracts and ocular hypertension
• Weight at every visit

The ACR 2022 guideline on the prevention and treatment of glucocorticoid-induced osteoporosis recommends starting bisphosphonate therapy in high-risk patients (age 40 and older with a FRAX 10-year major osteoporotic fracture probability of at least 10%) who are expected to take 7.5 mg/day of prednisone-equivalent for 3 months or longer.

Patients should carry a medical alert card or wear a bracelet indicating corticosteroid use if they have been on prednisone for more than 4 weeks at any dose above 5 mg/day. Sick-day rules, including when to double the dose and when to seek emergency care, should be reviewed at every clinic visit.